In this context, changes in BA composition could also be one reason for altered intestinal FXR signaling, expressed as reduced FGF19 levels, in our overweight and obese NAFLD patients. The gene discussed is FGF19; the disease is metabolic dysfunction-associated steatotic liver disease.